Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or immediate new fundraising through debt or equity in the provided pages. The company highlights strong free cash flow generation (Rs. 924 crore over nine months), which is being used for expansion and dividends. Expansion projects (Dwarka, Nanavati, Gurgaon, Mohali, Saket Complex) are largely funded through internal cash flows, with no indication of new external financing. Abhay Soi mentioned having sufficient wherewithal to add 3-4 hospitals within 1-2 years without stressing the balance sheet. For Lucknow, large-scale future capacity expansions p

Future growth expectations in sales/revenue/volumes?

Network gross revenue grew 16% YoY for the nine months ended Dec 2023; Q3 revenue grew 14% YoY. Average Revenue Per Occupied Bed (ARPOB) is expected to grow reasonably at 9-10% driven by price increases, OPD growth, oncology growth, and improved case/channel mix. International patient revenue grew 25% YoY, supporting revenue growth. Expansion adding around 800-1000 beds over next 5-6 years expected to be quickly absorbed due to high demand and occupancy constraints. Brownfield expansions like Shalimar Bagh show new beds ramp up quickly and contribute positive EBITDA and operating margins. Onco

Future growth expectations in earnings/operating earnings/profits/EPS?

Max Healthcare expects a robust Q4, benefiting from seasonality effects (Q2 and Q4 are typically strongest). Existing hospitals are expected to see continued revenue growth and operating leverage, with around 7% cost growth. New hospital beds (about 8% capacity increase) will start with lower ARPOB and negative EBITDA, breakeven expected within 6-12 months, which could temporarily temper margin expansion. EBITDA per bed is improving, with a 15% increase noted recently, driven by case mix, ARPOB increases, and operating leverage. Institutional business shows strong ARPOB growth (about 9-10%), a

Current/ Expected Orderbook/ Pending Orders?

No explicit mention of current or expected order book or pending orders was found in the provided transcript excerpts. The discussion primarily focuses on expansion projects, hospital bed capacity, acquisitions (e.g., Lucknow hospital), and operational performance. Capex updates note Rs. 300 crore spent in nine months FY24 against a Rs. 900 crore guidance, with multiple hospitals (Dwarka, Nanavati, Gurgaon, Mohali) expected to commission in FY25. No detailed order book figures or pending order specifics related to contracts or procurement are disclosed in the text. Expansion involves organic g

Max HealthcareQ3 FY24Healthcare Services

Max Healthcare Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹941P/E: 65.9Market Cap: ₹98.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Network gross revenue grew 16% YoY for the nine months ended Dec 2023; Q3 revenue grew 14% YoY.
Average Revenue Per Occupied Bed (ARPOB) is expected to grow reasonably at 9-10% driven by price increases, OPD growth, oncology growth, and improved case/channel mix.
International patient revenue grew 25% YoY, supporting revenue growth.
Expansion adding around 800-1000 beds over next 5-6 years expected to be quickly absorbed due to high demand and occupancy constraints.
Brownfield expansions like Shalimar Bagh show new beds ramp up quickly and contribute positive EBITDA and operating margins.
Oncology, including robotics and immunotherapy, is a key growth driver, with higher EBITDA per bed.
Institutional business tariffs may be revised upwards, potentially increasing revenue.
Seasonal patterns: Q2 & Q4 typically strongest quarters.
Overall, a robust Q4 is expected due to seasonality and continued growth momentum.

Margin guidance

Category 3

Max Healthcare expects a robust Q4, benefiting from seasonality effects (Q2 and Q4 are typically strongest).
Existing hospitals are expected to see continued revenue growth and operating leverage, with around 7% cost growth.
New hospital beds (about 8% capacity increase) will start with lower ARPOB and negative EBITDA, breakeven expected within 6-12 months, which could temporarily temper margin expansion.
EBITDA per bed is improving, with a 15% increase noted recently, driven by case mix, ARPOB increases, and operating leverage.
Institutional business shows strong ARPOB growth (about 9-10%), and oncology and international patient growth remain key drivers.
Margin improvement may be stable to moderate in FY25, balanced between mature hospital growth and new hospital ramp-ups.
Overall, earnings growth will continue but moderated by new capacity commissioning costs.

See what Max Healthcare management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or immediate new fundraising through debt or equity in the provided pages.
The company highlights strong free cash flow generation (Rs. 924 crore over nine months), which is being used for expansion and dividends.
Expansion projects (Dwarka, Nanavati, Gurgaon, Mohali, Saket Complex) are largely funded through internal cash flows, with no indication of new external financing.
Abhay Soi mentioned having sufficient wherewithal to add 3-4 hospitals within 1-2 years without stressing the balance sheet.
For Lucknow, large-scale future capacity expansions post FY28 are described as potential, with no approved CAPEX or Board approvals currently.
Overall, the company appears financially comfortable funding growth organically without aggressive external fundraising plans at this time.

Order book

No explicit mention of current or expected order book or pending orders was found in the provided transcript excerpts.
The discussion primarily focuses on expansion projects, hospital bed capacity, acquisitions (e.g., Lucknow hospital), and operational performance.
Capex updates note Rs. 300 crore spent in nine months FY24 against a Rs. 900 crore guidance, with multiple hospitals (Dwarka, Nanavati, Gurgaon, Mohali) expected to commission in FY25.
No detailed order book figures or pending order specifics related to contracts or procurement are disclosed in the text.
Expansion involves organic growth and opportunistic acquisitions, with active but not aggressive pursuit of opportunities in new cities.

See what Max Healthcare management said on order book — free account, 30 seconds.

Capex plans

Yes

- Dwarka hospital (300 beds): Near commissioning; asset-light model with lease contract; minimal future CAPEX expected; finishing in progress. - Nanavati (329 beds): Basement and ground level completed; steel fabrication started; on schedule. - Sector-56 Gurgaon (300 beds): Structural drawing approved; RCC works commenced; on schedule. - Mohali (190 beds): Design finalized; base raft concrete started; on schedule. - Max Smart (Saket Complex, 350 beds): Tree transplantation underway; existing structures demolished; project progressing after initial delay. - Max Vikrant (Saket Complex, 300 beds): Revised building plans submitted; infrastructure dues paid; contractor tenders under review; Forest department NOC applied. - Expected CAPEX for FY24 is Rs. 900 crore (tracking Rs. 300 crore so far). - Lucknow expansion has land for significant future capacity (up to 3500 beds possible post-2028); construction and expansion will be phased. - Brownfield expansions like Shalimar Bagh are preferred for quicker bed additions with better operating leverage. Overall, multiple large-scale projects are underway with planned commissioning over next 1-3 years and further strategic expansions contemplated.

Track Max Healthcare — get its next earnings analysis in your feed

How does Max Healthcare rank vs peers in Healthcare Services?

Pro feature

ThisMax Healthcare

Rev 3Mar 3

See where Max Healthcare sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Max Healthcare rank in Healthcare Services?

Compare Max Healthcare against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Max Healthcare's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Manipal Health vs Aster DM Quality

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Max Healthcare Q3 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Max Healthcare rank in Healthcare Services?

Continue your research

What Max Healthcare's management said in earlier quarters

Others in Healthcare Services this season